Back to discover
Drug

Octopamine

Research stage
Emerging research

Also known as Norsynephrine.

1
Research papers
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this drug.

Synapse-specific catecholaminergic modulation of neuronal glutamate release.

Research2024-12-30Proceedings of the National Academy of Sciences of the United States of America

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name
Octopamine
Aliases & brands
Norsynephrine
RxNorm CUI
1311141
ChEMBL ID
CHEMBL53929
ATC codes
C01CA18
UNII
14O50WS8JD

Research activity

1 papers

Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.

Most influential

Synapse-specific catecholaminergic modulation of neuronal glutamate release.

Proceedings of the National Academy of Sciences of the United States of America · 2025 · 8 cites
Recent papers

Synapse-specific catecholaminergic modulation of neuronal glutamate release.

Proceedings of the National Academy of Sciences of the United States of America · 2025 · 8 cites
Major research themes5
Glutamic Acid1Motor Neurons1Octopamine1Receptors, Biogenic Amine1Synapses1
Journals, researchers & institutions
Top journals
  • Proceedings of the National Academy of Sciences of the United States of America1
Leading researchers
  • Bakshinska D1
  • Cypranowska C1
  • Hoagland A1
  • Isacoff EY1
  • Liu WY1
  • Newman ZL1
  • Schultz R1
  • Stanley C1
Leading institutions
free-text, unnormalised
  • Helen Wills Neuroscience Institute1
  • Lawrence Berkeley National Laboratory1
  • Montana State University1
  • University of California1
  • University of California Berkeley1
References & data sources
  • RxNorm (U.S. National Library of Medicine) — drug identity
  • ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
  • Europe PMC — research literature